Veru Inc. announced a strategic shift in its drug development pipeline for its oral agent, sabizabulin. Based on new positive preclinical data showing efficacy against daraxonrasib-resistant cancer cells, the company will advance sabizabulin as a potential treatment for metastatic pancreatic cancer. Consequently, Veru will discontinue the exploration of sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease.
Key Details
- Positive Preclinical Data: New studies demonstrated that sabizabulin has potent anticancer activity (IC50=18.2nM) in human pancreatic cancer cell lines that are resistant to daraxonrasib (RASONQUE™).
- Strategic Reprioritization: The company will now focus on developing sabizabulin for patients with metastatic pancreatic cancer that has progressed after treatment with daraxonrasib, a large unmet medical need.
- Next Steps: Veru plans to initiate a Phase 2b clinical trial for this new indication and will seek regulatory guidance from the FDA through a pre-IND meeting in Q4 2026.